Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Cardiac allograft vasculopathy and insulin resistance - Hope for new therapeutic targets ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA Potena, L., Valantine, H. A. 2007; 36 (4): 965-?

Abstract

Cardiac allograft vasculopathy (CAV) is a major cause of death in patients surviving more than 1 year after heart transplantation. An important cluster of CAV risk factors occurs as a consequence of insulin resistance and manifests as part of the metabolic syndrome. This article summarizes the pathologic features of CAV and reviews the contribution of the major components of insulin resistance in CAV development and progression. It focuses on the few studies that have analyzed the impact of the individual metabolic abnormalities and inflammation and on therapeutic strategies to minimize the clinical manifestation of insulin resistance after heart transplantation.

View details for DOI 10.1016/.j.ecl.2007.07.012

View details for Web of Science ID 000251518300008

View details for PubMedID 17983931

View details for PubMedCentralID PMC3785936